Isentress tablets<unk>  was initially approved only for use in individuals whose infection has proven resistant to other HAART drugs. However, in July 2009, the U.S. Food and Drug Administration (FDA) granted expanded approval for<unk>  for use in all patients. As with any HAART medication,<unk>  is unlikely to show durability if used as monotherapy, due to the highly mutagenic nature of HIV. In December 2011, it approval for use in children over the age of two, taken in pill form orally twice a day by prescription with two other antiretroviral medications to form the cocktail (most anti-HIV drugs regimens for adults and children use these cocktails).<unk>  is available in chewable form, but because the two tablet formulations are not interchangeable, the chewable pills are only approved for use in children two to 11. Older adolescents will use the adult formulation. Efficacy In a study of the drug as part of combination therapy,<unk>  exhibited potent and durable antiretroviral activity similar to that of efavirenz at 24 and 48 weeks but achieved HIV-1 RNA levels below detection at a more rapid rate. After 24 and 48 weeks of treatment,<unk>  did not result in increased serum levels of total cholesterol, low-density lipoprotein cholesterol, or triglycerides.
Raltegravir
Saquinavir
Fosamprenavir
Entecavir
Coronavir
Maribavir
Sorivudine
Telbivudine